| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Immunoglobulin G | 118 | 2024 | 4560 | 14.090 |
Why?
|
| Giant Cell Arteritis | 40 | 2023 | 292 | 11.070 |
Why?
|
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 48 | 2024 | 220 | 10.260 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 52 | 2024 | 288 | 8.370 |
Why?
|
| Autoimmune Diseases | 53 | 2024 | 2133 | 8.260 |
Why?
|
| Glucocorticoids | 76 | 2024 | 2107 | 7.360 |
Why?
|
| Prednisone | 35 | 2023 | 1574 | 4.940 |
Why?
|
| Plasma Cells | 23 | 2023 | 591 | 4.500 |
Why?
|
| Vasculitis | 32 | 2024 | 519 | 4.440 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 28 | 2023 | 693 | 3.190 |
Why?
|
| Myeloblastin | 22 | 2023 | 101 | 3.010 |
Why?
|
| Microscopic Polyangiitis | 15 | 2024 | 45 | 2.880 |
Why?
|
| Antirheumatic Agents | 24 | 2021 | 1339 | 2.670 |
Why?
|
| Receptors, Interleukin-6 | 8 | 2020 | 224 | 2.460 |
Why?
|
| Immunologic Factors | 25 | 2018 | 1580 | 2.450 |
Why?
|
| Rheumatology | 16 | 2022 | 576 | 2.430 |
Why?
|
| Cyclophosphamide | 36 | 2023 | 2242 | 2.330 |
Why?
|
| Polymyalgia Rheumatica | 5 | 2021 | 54 | 2.310 |
Why?
|
| Immune System Diseases | 9 | 2023 | 262 | 2.310 |
Why?
|
| Paraproteinemias | 7 | 2016 | 246 | 2.300 |
Why?
|
| Peroxidase | 13 | 2020 | 611 | 2.160 |
Why?
|
| Immunosuppressive Agents | 40 | 2023 | 4149 | 1.970 |
Why?
|
| Temporal Arteries | 7 | 2020 | 128 | 1.810 |
Why?
|
| Nipecotic Acids | 2 | 2023 | 38 | 1.800 |
Why?
|
| Remission Induction | 42 | 2023 | 2386 | 1.800 |
Why?
|
| Retroperitoneal Fibrosis | 7 | 2019 | 37 | 1.720 |
Why?
|
| B-Lymphocytes | 27 | 2023 | 4665 | 1.700 |
Why?
|
| Aortitis | 5 | 2019 | 74 | 1.660 |
Why?
|
| Hypergammaglobulinemia | 6 | 2017 | 74 | 1.520 |
Why?
|
| Agglutination Tests | 3 | 2014 | 41 | 1.500 |
Why?
|
| Orbital Pseudotumor | 5 | 2020 | 42 | 1.480 |
Why?
|
| Meningitis | 4 | 2018 | 216 | 1.470 |
Why?
|
| Diagnostic Errors | 5 | 2018 | 1257 | 1.270 |
Why?
|
| Humans | 382 | 2024 | 744343 | 1.260 |
Why?
|
| Takayasu Arteritis | 9 | 2021 | 96 | 1.260 |
Why?
|
| Azathioprine | 16 | 2023 | 353 | 1.260 |
Why?
|
| Fibrosis | 23 | 2023 | 2029 | 1.250 |
Why?
|
| Orbital Myositis | 3 | 2018 | 20 | 1.180 |
Why?
|
| Anti-Inflammatory Agents | 12 | 2021 | 1790 | 1.110 |
Why?
|
| Drug Therapy, Combination | 27 | 2021 | 6489 | 1.100 |
Why?
|
| CD4-Positive T-Lymphocytes | 13 | 2020 | 4386 | 1.100 |
Why?
|
| Lupus Erythematosus, Systemic | 15 | 2024 | 2104 | 1.050 |
Why?
|
| Sialadenitis | 7 | 2019 | 43 | 1.030 |
Why?
|
| B-Lymphocyte Subsets | 2 | 2023 | 246 | 1.010 |
Why?
|
| Severity of Illness Index | 27 | 2021 | 15540 | 0.970 |
Why?
|
| Middle Aged | 166 | 2023 | 213383 | 0.950 |
Why?
|
| Polyarteritis Nodosa | 7 | 2021 | 66 | 0.940 |
Why?
|
| Eosinophilia | 5 | 2023 | 541 | 0.900 |
Why?
|
| Polychondritis, Relapsing | 2 | 2013 | 28 | 0.900 |
Why?
|
| Pharmacogenetics | 2 | 2017 | 675 | 0.890 |
Why?
|
| Male | 196 | 2023 | 350118 | 0.890 |
Why?
|
| Diagnosis, Differential | 47 | 2022 | 12959 | 0.890 |
Why?
|
| Terminology as Topic | 5 | 2013 | 1547 | 0.860 |
Why?
|
| Arteritis | 2 | 2023 | 159 | 0.860 |
Why?
|
| Recurrence | 30 | 2023 | 8340 | 0.820 |
Why?
|
| Female | 188 | 2023 | 380194 | 0.820 |
Why?
|
| Aged | 119 | 2023 | 163280 | 0.810 |
Why?
|
| T-Lymphocytes, Cytotoxic | 8 | 2023 | 1821 | 0.800 |
Why?
|
| Double-Blind Method | 27 | 2023 | 12026 | 0.790 |
Why?
|
| Inflammation | 14 | 2024 | 10638 | 0.790 |
Why?
|
| Aniline Compounds | 2 | 2023 | 986 | 0.790 |
Why?
|
| Glomerulonephritis, Membranous | 3 | 2020 | 86 | 0.740 |
Why?
|
| Headache | 7 | 2022 | 1226 | 0.710 |
Why?
|
| Scleroderma, Systemic | 5 | 2021 | 323 | 0.700 |
Why?
|
| Treatment Outcome | 52 | 2023 | 63114 | 0.700 |
Why?
|
| Methotrexate | 10 | 2015 | 1727 | 0.690 |
Why?
|
| Receptors, Tumor Necrosis Factor | 11 | 2012 | 595 | 0.690 |
Why?
|
| Lymphocytosis | 2 | 2017 | 119 | 0.670 |
Why?
|
| Malignant Atrophic Papulosis | 3 | 2015 | 7 | 0.670 |
Why?
|
| Antibodies, Monoclonal | 14 | 2023 | 9274 | 0.660 |
Why?
|
| Disabled Persons | 5 | 2014 | 1212 | 0.660 |
Why?
|
| Immunity, Cellular | 2 | 2015 | 1607 | 0.640 |
Why?
|
| Autoantibodies | 11 | 2021 | 2035 | 0.640 |
Why?
|
| Acute-Phase Proteins | 1 | 2019 | 262 | 0.630 |
Why?
|
| Purpura | 3 | 2017 | 122 | 0.630 |
Why?
|
| Vascular Diseases | 3 | 2016 | 1161 | 0.620 |
Why?
|
| Sjogren's Syndrome | 9 | 2022 | 233 | 0.600 |
Why?
|
| Antibody Specificity | 1 | 2019 | 1095 | 0.600 |
Why?
|
| Edema | 4 | 2017 | 789 | 0.590 |
Why?
|
| Rehabilitation | 2 | 2009 | 134 | 0.590 |
Why?
|
| Behcet Syndrome | 4 | 2016 | 84 | 0.590 |
Why?
|
| Rheumatic Diseases | 5 | 2022 | 592 | 0.590 |
Why?
|
| Adult | 108 | 2023 | 214055 | 0.580 |
Why?
|
| Anti-Infective Agents | 2 | 2019 | 972 | 0.580 |
Why?
|
| Biopsy | 24 | 2021 | 6756 | 0.580 |
Why?
|
| Precursor Cells, B-Lymphoid | 1 | 2017 | 98 | 0.580 |
Why?
|
| Nephritis, Interstitial | 2 | 2020 | 156 | 0.580 |
Why?
|
| Autoimmune Diseases of the Nervous System | 1 | 2017 | 67 | 0.580 |
Why?
|
| Kidney Diseases | 7 | 2020 | 2149 | 0.550 |
Why?
|
| Receptors, Cholinergic | 1 | 2017 | 238 | 0.550 |
Why?
|
| Prednisolone | 5 | 2016 | 334 | 0.550 |
Why?
|
| Hereditary Central Nervous System Demyelinating Diseases | 1 | 2016 | 39 | 0.540 |
Why?
|
| Skin Diseases | 2 | 2022 | 1065 | 0.540 |
Why?
|
| Peripheral Nervous System Diseases | 3 | 2018 | 685 | 0.540 |
Why?
|
| Dacryocystitis | 4 | 2019 | 70 | 0.530 |
Why?
|
| Blindness | 2 | 2018 | 617 | 0.520 |
Why?
|
| Intracranial Hypertension | 1 | 2018 | 186 | 0.520 |
Why?
|
| Dermatomyositis | 2 | 2014 | 224 | 0.510 |
Why?
|
| Exodeoxyribonucleases | 1 | 2016 | 180 | 0.500 |
Why?
|
| Th2 Cells | 2 | 2017 | 1061 | 0.500 |
Why?
|
| Retroperitoneal Space | 5 | 2020 | 176 | 0.500 |
Why?
|
| Granuloma, Lethal Midline | 1 | 2014 | 4 | 0.490 |
Why?
|
| Disease Progression | 15 | 2022 | 13284 | 0.490 |
Why?
|
| Myasthenia Gravis | 1 | 2017 | 199 | 0.490 |
Why?
|
| Central Nervous System Diseases | 2 | 2018 | 518 | 0.480 |
Why?
|
| Immunity, Humoral | 2 | 2021 | 598 | 0.480 |
Why?
|
| Eosinophils | 3 | 2016 | 955 | 0.470 |
Why?
|
| Hypersensitivity, Immediate | 2 | 2013 | 337 | 0.470 |
Why?
|
| Speech-Language Pathology | 1 | 2014 | 25 | 0.470 |
Why?
|
| Ethmoid Sinusitis | 1 | 2013 | 25 | 0.470 |
Why?
|
| Churg-Strauss Syndrome | 4 | 2021 | 70 | 0.460 |
Why?
|
| Glomerulonephritis | 4 | 2018 | 372 | 0.460 |
Why?
|
| Aorta | 5 | 2024 | 2061 | 0.460 |
Why?
|
| Immunoglobulin E | 4 | 2022 | 1463 | 0.450 |
Why?
|
| Blood Sedimentation | 7 | 2020 | 231 | 0.450 |
Why?
|
| Serum Sickness | 1 | 2013 | 28 | 0.450 |
Why?
|
| Disability Evaluation | 5 | 2014 | 1827 | 0.450 |
Why?
|
| Adrenal Insufficiency | 1 | 2015 | 184 | 0.440 |
Why?
|
| Eye Diseases | 3 | 2020 | 669 | 0.440 |
Why?
|
| Heart Valve Diseases | 1 | 2021 | 1073 | 0.440 |
Why?
|
| Myofibroblasts | 1 | 2014 | 222 | 0.430 |
Why?
|
| Occupational Therapy | 1 | 2014 | 134 | 0.420 |
Why?
|
| Evidence-Based Medicine | 9 | 2022 | 3610 | 0.420 |
Why?
|
| Mitral Valve | 1 | 2021 | 1491 | 0.420 |
Why?
|
| Kidney Failure, Chronic | 10 | 2022 | 2538 | 0.420 |
Why?
|
| Submandibular Gland | 3 | 2016 | 86 | 0.420 |
Why?
|
| Pancreatitis | 4 | 2013 | 1092 | 0.410 |
Why?
|
| Scleritis | 4 | 2020 | 100 | 0.410 |
Why?
|
| Health Status | 6 | 2019 | 4034 | 0.410 |
Why?
|
| Autoantigens | 6 | 2021 | 892 | 0.390 |
Why?
|
| Lipid Metabolism | 1 | 2019 | 1889 | 0.380 |
Why?
|
| Trigeminal Nerve Diseases | 1 | 2011 | 55 | 0.380 |
Why?
|
| Cardiomyopathies | 1 | 2023 | 1912 | 0.380 |
Why?
|
| Molecular Targeted Therapy | 3 | 2017 | 2727 | 0.380 |
Why?
|
| Aortic Valve | 1 | 2021 | 1922 | 0.380 |
Why?
|
| Orbital Diseases | 2 | 2011 | 181 | 0.380 |
Why?
|
| Coproporphyria, Hereditary | 1 | 2010 | 2 | 0.380 |
Why?
|
| Cultural Competency | 1 | 2014 | 289 | 0.380 |
Why?
|
| Cytochrome P-450 Enzyme System | 3 | 2017 | 419 | 0.380 |
Why?
|
| Kidney Transplantation | 8 | 2021 | 4251 | 0.370 |
Why?
|
| International Classification of Diseases | 2 | 2008 | 867 | 0.370 |
Why?
|
| Skin Diseases, Vascular | 2 | 2001 | 39 | 0.370 |
Why?
|
| Epilepsy, Tonic-Clonic | 1 | 2010 | 49 | 0.370 |
Why?
|
| Faculty | 1 | 2014 | 386 | 0.370 |
Why?
|
| Interdisciplinary Communication | 1 | 2016 | 950 | 0.370 |
Why?
|
| Hypesthesia | 2 | 2010 | 109 | 0.370 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2021 | 1536 | 0.360 |
Why?
|
| Thyroiditis | 1 | 2010 | 85 | 0.360 |
Why?
|
| Drug Administration Schedule | 7 | 2018 | 4933 | 0.350 |
Why?
|
| Physical Therapy Modalities | 1 | 2014 | 550 | 0.350 |
Why?
|
| Retinal Diseases | 1 | 2016 | 683 | 0.350 |
Why?
|
| Sensitivity and Specificity | 14 | 2020 | 14722 | 0.350 |
Why?
|
| Asthma | 4 | 2023 | 6011 | 0.350 |
Why?
|
| Flow Cytometry | 7 | 2021 | 5974 | 0.350 |
Why?
|
| Receptors, IgG | 3 | 2017 | 582 | 0.350 |
Why?
|
| Decision Support Techniques | 4 | 2021 | 1956 | 0.350 |
Why?
|
| Tumor Necrosis Factor-alpha | 7 | 2016 | 4420 | 0.340 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2017 | 1660 | 0.340 |
Why?
|
| Fever | 6 | 2013 | 1616 | 0.340 |
Why?
|
| Jaundice | 1 | 2009 | 89 | 0.330 |
Why?
|
| Lacrimal Apparatus | 3 | 2020 | 225 | 0.330 |
Why?
|
| Cyclosporine | 4 | 2001 | 786 | 0.330 |
Why?
|
| Pain | 6 | 2017 | 4986 | 0.330 |
Why?
|
| Holistic Health | 2 | 2006 | 47 | 0.330 |
Why?
|
| Paranasal Sinuses | 1 | 2011 | 250 | 0.320 |
Why?
|
| Gastrointestinal Diseases | 4 | 2021 | 1170 | 0.320 |
Why?
|
| Antiphospholipid Syndrome | 4 | 2015 | 173 | 0.320 |
Why?
|
| Thyroid Diseases | 2 | 2010 | 379 | 0.320 |
Why?
|
| Thromboembolism | 1 | 2015 | 986 | 0.320 |
Why?
|
| Atrioventricular Block | 1 | 2010 | 120 | 0.320 |
Why?
|
| Aorta, Thoracic | 3 | 2013 | 1082 | 0.320 |
Why?
|
| Blepharoptosis | 1 | 2009 | 143 | 0.320 |
Why?
|
| Exanthema | 8 | 2020 | 501 | 0.320 |
Why?
|
| Borrelia burgdorferi | 1 | 2010 | 180 | 0.320 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2011 | 523 | 0.310 |
Why?
|
| Radiography | 11 | 2020 | 7023 | 0.310 |
Why?
|
| Treatment Failure | 5 | 2021 | 2618 | 0.310 |
Why?
|
| Orbit | 2 | 2023 | 426 | 0.310 |
Why?
|
| Blister | 2 | 2023 | 86 | 0.310 |
Why?
|
| Management Information Systems | 1 | 2008 | 50 | 0.310 |
Why?
|
| Pneumocystis carinii | 1 | 2008 | 74 | 0.310 |
Why?
|
| Body Composition | 1 | 2017 | 2401 | 0.310 |
Why?
|
| Respiratory System | 1 | 2011 | 557 | 0.310 |
Why?
|
| Pancreas | 4 | 2020 | 1686 | 0.300 |
Why?
|
| Hepatitis B | 1 | 2013 | 695 | 0.300 |
Why?
|
| Vision, Low | 1 | 2009 | 168 | 0.300 |
Why?
|
| Program Development | 1 | 2014 | 1316 | 0.300 |
Why?
|
| Otorhinolaryngologic Diseases | 2 | 2019 | 90 | 0.290 |
Why?
|
| Leg | 3 | 2020 | 1116 | 0.290 |
Why?
|
| Thyroid Gland | 2 | 2012 | 1173 | 0.290 |
Why?
|
| Methylprednisolone | 5 | 2015 | 387 | 0.290 |
Why?
|
| Interleukin-6 | 5 | 2022 | 3200 | 0.290 |
Why?
|
| Phosphoproteins | 1 | 2016 | 2440 | 0.290 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 2 | 2022 | 546 | 0.290 |
Why?
|
| Vomiting | 1 | 2010 | 636 | 0.290 |
Why?
|
| Syncope | 1 | 2010 | 429 | 0.290 |
Why?
|
| Pulmonary Fibrosis | 2 | 2010 | 530 | 0.290 |
Why?
|
| Tongue | 1 | 2010 | 406 | 0.290 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2008 | 249 | 0.290 |
Why?
|
| Consensus | 6 | 2022 | 2959 | 0.280 |
Why?
|
| Multiple Organ Failure | 1 | 2009 | 390 | 0.280 |
Why?
|
| Lupus Vulgaris | 1 | 2006 | 9 | 0.280 |
Why?
|
| Cholangitis | 2 | 2021 | 108 | 0.280 |
Why?
|
| Oral Ulcer | 3 | 2013 | 96 | 0.280 |
Why?
|
| Salivary Gland Diseases | 1 | 2006 | 37 | 0.280 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 6 | 2021 | 3870 | 0.280 |
Why?
|
| Ankle Joint | 1 | 2010 | 411 | 0.270 |
Why?
|
| Quality of Life | 7 | 2023 | 12804 | 0.270 |
Why?
|
| Aged, 80 and over | 28 | 2021 | 57776 | 0.270 |
Why?
|
| Periodicals as Topic | 2 | 2008 | 1432 | 0.270 |
Why?
|
| Immunocompromised Host | 2 | 2008 | 847 | 0.270 |
Why?
|
| Kidney | 9 | 2021 | 7186 | 0.260 |
Why?
|
| Electronic Mail | 1 | 2007 | 213 | 0.260 |
Why?
|
| Serologic Tests | 2 | 2020 | 374 | 0.260 |
Why?
|
| Ehrlichia chaffeensis | 1 | 2004 | 3 | 0.260 |
Why?
|
| Adrenal Gland Diseases | 1 | 2006 | 138 | 0.260 |
Why?
|
| Lung | 6 | 2020 | 9856 | 0.260 |
Why?
|
| Cryoglobulinemia | 3 | 2013 | 87 | 0.260 |
Why?
|
| Pathology, Clinical | 1 | 2008 | 368 | 0.250 |
Why?
|
| Exophthalmos | 2 | 2018 | 97 | 0.250 |
Why?
|
| Ehrlichiosis | 1 | 2004 | 29 | 0.250 |
Why?
|
| Lymphocyte Depletion | 3 | 2017 | 608 | 0.250 |
Why?
|
| Sclerosis | 4 | 2015 | 213 | 0.250 |
Why?
|
| Culture | 1 | 2009 | 633 | 0.250 |
Why?
|
| Hospital Mortality | 2 | 2017 | 5317 | 0.250 |
Why?
|
| Retrospective Studies | 24 | 2023 | 77449 | 0.250 |
Why?
|
| Cytokines | 8 | 2018 | 7322 | 0.250 |
Why?
|
| Renal Insufficiency | 2 | 2023 | 804 | 0.250 |
Why?
|
| Cytoplasm | 2 | 2019 | 1539 | 0.240 |
Why?
|
| Pulmonary Alveoli | 1 | 2007 | 675 | 0.240 |
Why?
|
| Mastoiditis | 2 | 2016 | 34 | 0.240 |
Why?
|
| Ions | 1 | 2005 | 265 | 0.240 |
Why?
|
| Deglutition Disorders | 1 | 2010 | 605 | 0.240 |
Why?
|
| Hospital Administration | 1 | 2008 | 353 | 0.240 |
Why?
|
| Lyme Disease | 1 | 2010 | 621 | 0.240 |
Why?
|
| Lymphocyte Count | 6 | 2018 | 793 | 0.230 |
Why?
|
| Phlebitis | 2 | 2014 | 31 | 0.230 |
Why?
|
| Infusions, Intravenous | 3 | 2020 | 2274 | 0.230 |
Why?
|
| alpha 1-Antitrypsin | 2 | 2017 | 164 | 0.230 |
Why?
|
| Skin | 6 | 2020 | 4364 | 0.230 |
Why?
|
| Female Urogenital Diseases | 2 | 2008 | 52 | 0.230 |
Why?
|
| Randomized Controlled Trials as Topic | 14 | 2022 | 9959 | 0.230 |
Why?
|
| Pilot Projects | 5 | 2023 | 8324 | 0.230 |
Why?
|
| Delirium | 1 | 2015 | 1609 | 0.220 |
Why?
|
| Hallucinations | 1 | 2006 | 360 | 0.220 |
Why?
|
| Inpatients | 1 | 2015 | 2518 | 0.220 |
Why?
|
| Panniculitis, Peritoneal | 1 | 2022 | 11 | 0.220 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2008 | 639 | 0.220 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2012 | 1186 | 0.220 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2020 | 2208 | 0.220 |
Why?
|
| Biological Products | 3 | 2020 | 860 | 0.220 |
Why?
|
| Antineoplastic Agents | 2 | 2023 | 13695 | 0.220 |
Why?
|
| Prospective Studies | 17 | 2023 | 53288 | 0.220 |
Why?
|
| Panuveitis | 2 | 2014 | 32 | 0.220 |
Why?
|
| Sex Factors | 4 | 2021 | 10397 | 0.220 |
Why?
|
| Arthritis, Rheumatoid | 7 | 2021 | 3712 | 0.220 |
Why?
|
| Blood Vessels | 2 | 2007 | 1125 | 0.210 |
Why?
|
| Chlamydophila Infections | 1 | 2002 | 23 | 0.210 |
Why?
|
| Organ Specificity | 2 | 2020 | 2008 | 0.210 |
Why?
|
| Antigens, CD20 | 2 | 2020 | 199 | 0.210 |
Why?
|
| Physician-Patient Relations | 2 | 2007 | 3229 | 0.210 |
Why?
|
| Muscle, Skeletal | 2 | 2014 | 4931 | 0.210 |
Why?
|
| Chlamydophila pneumoniae | 1 | 2002 | 55 | 0.210 |
Why?
|
| Information Storage and Retrieval | 1 | 2008 | 824 | 0.210 |
Why?
|
| Cohort Studies | 17 | 2023 | 40561 | 0.210 |
Why?
|
| Immunotherapy | 2 | 2016 | 4445 | 0.210 |
Why?
|
| Cell Count | 3 | 2015 | 1856 | 0.210 |
Why?
|
| Hemorrhage | 2 | 2019 | 3461 | 0.200 |
Why?
|
| Leukocyte Count | 2 | 2016 | 1588 | 0.200 |
Why?
|
| Fluorescent Antibody Technique | 3 | 2021 | 2505 | 0.200 |
Why?
|
| Fibroblasts | 4 | 2020 | 4161 | 0.200 |
Why?
|
| Abdomen, Acute | 1 | 2002 | 123 | 0.200 |
Why?
|
| Neurology | 2 | 2022 | 763 | 0.200 |
Why?
|
| Incidental Findings | 1 | 2006 | 689 | 0.200 |
Why?
|
| Lung Diseases | 3 | 2019 | 1886 | 0.190 |
Why?
|
| Proteomics | 2 | 2005 | 3638 | 0.190 |
Why?
|
| Case-Control Studies | 16 | 2022 | 21746 | 0.190 |
Why?
|
| False Negative Reactions | 2 | 2014 | 588 | 0.190 |
Why?
|
| Public Policy | 1 | 2005 | 572 | 0.190 |
Why?
|
| Antigens, CD19 | 1 | 2023 | 380 | 0.190 |
Why?
|
| Vasculitis, Leukocytoclastic, Cutaneous | 1 | 2000 | 41 | 0.190 |
Why?
|
| Biological Factors | 1 | 2002 | 164 | 0.190 |
Why?
|
| Prognosis | 14 | 2021 | 29063 | 0.190 |
Why?
|
| IgG Deficiency | 1 | 2020 | 28 | 0.190 |
Why?
|
| Professional-Patient Relations | 1 | 2006 | 737 | 0.180 |
Why?
|
| Diplopia | 2 | 2018 | 200 | 0.180 |
Why?
|
| Intubation | 1 | 2020 | 141 | 0.180 |
Why?
|
| Young Adult | 20 | 2021 | 56430 | 0.180 |
Why?
|
| Hematuria | 2 | 2020 | 235 | 0.180 |
Why?
|
| Registries | 5 | 2021 | 8089 | 0.180 |
Why?
|
| Deafness | 1 | 2004 | 458 | 0.180 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2021 | 262 | 0.180 |
Why?
|
| Labyrinthitis | 1 | 2000 | 29 | 0.180 |
Why?
|
| Spinal Puncture | 3 | 2018 | 281 | 0.180 |
Why?
|
| Respiratory Therapy | 1 | 2020 | 132 | 0.180 |
Why?
|
| Immunoglobulin Isotypes | 1 | 2020 | 158 | 0.180 |
Why?
|
| Blood Proteins | 2 | 2007 | 1124 | 0.170 |
Why?
|
| Neoplasms | 7 | 2022 | 21683 | 0.170 |
Why?
|
| Coronavirus | 1 | 2022 | 158 | 0.170 |
Why?
|
| Mikulicz' Disease | 1 | 2019 | 8 | 0.170 |
Why?
|
| Receptors, Phospholipase A2 | 1 | 2019 | 33 | 0.170 |
Why?
|
| Biliary Tract | 1 | 2020 | 134 | 0.170 |
Why?
|
| Nervous System Diseases | 2 | 2022 | 1622 | 0.170 |
Why?
|
| Predictive Value of Tests | 9 | 2022 | 15076 | 0.170 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2017 | 1838 | 0.170 |
Why?
|
| Macrophage Migration-Inhibitory Factors | 1 | 2018 | 108 | 0.160 |
Why?
|
| HELLP Syndrome | 1 | 1998 | 41 | 0.160 |
Why?
|
| Aneurysm | 1 | 2002 | 339 | 0.160 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2019 | 10943 | 0.160 |
Why?
|
| Receptors, Fc | 2 | 2020 | 541 | 0.160 |
Why?
|
| Venous Thrombosis | 3 | 2019 | 1239 | 0.160 |
Why?
|
| Syndrome | 3 | 2010 | 3251 | 0.160 |
Why?
|
| Peptide Hydrolases | 1 | 2021 | 634 | 0.160 |
Why?
|
| Lymphoma | 2 | 2017 | 1877 | 0.160 |
Why?
|
| Mass Spectrometry | 2 | 2018 | 2203 | 0.160 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2018 | 109 | 0.160 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 1 | 2000 | 177 | 0.160 |
Why?
|
| Apolipoprotein A-I | 1 | 2019 | 281 | 0.160 |
Why?
|
| Histoplasmosis | 1 | 1998 | 66 | 0.160 |
Why?
|
| Toes | 1 | 1999 | 206 | 0.160 |
Why?
|
| Ulcer | 2 | 2016 | 209 | 0.160 |
Why?
|
| Osteoarthropathy, Primary Hypertrophic | 1 | 1997 | 2 | 0.160 |
Why?
|
| Urine | 1 | 2019 | 370 | 0.150 |
Why?
|
| Apolipoproteins B | 1 | 2019 | 374 | 0.150 |
Why?
|
| Lupus Nephritis | 2 | 1998 | 310 | 0.150 |
Why?
|
| Pharynx | 2 | 2014 | 413 | 0.150 |
Why?
|
| Finger Joint | 2 | 2013 | 108 | 0.150 |
Why?
|
| Tomography, X-Ray Computed | 11 | 2018 | 20129 | 0.150 |
Why?
|
| Neoplasms, Plasma Cell | 1 | 2017 | 36 | 0.150 |
Why?
|
| Xanthomatosis | 1 | 2017 | 32 | 0.150 |
Why?
|
| Incidence | 9 | 2023 | 20947 | 0.150 |
Why?
|
| Digestive System Diseases | 1 | 2019 | 147 | 0.150 |
Why?
|
| Respiratory Insufficiency | 1 | 2006 | 1199 | 0.150 |
Why?
|
| Internet | 3 | 2015 | 3064 | 0.150 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2022 | 536 | 0.150 |
Why?
|
| Dysuria | 1 | 2016 | 6 | 0.150 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 1 | 2017 | 65 | 0.140 |
Why?
|
| Pyuria | 1 | 2016 | 30 | 0.140 |
Why?
|
| Antigens, CD | 4 | 2020 | 4026 | 0.140 |
Why?
|
| Leukocyte L1 Antigen Complex | 1 | 2017 | 88 | 0.140 |
Why?
|
| Disease Management | 4 | 2021 | 2459 | 0.140 |
Why?
|
| Aortic Aneurysm | 2 | 2013 | 643 | 0.140 |
Why?
|
| Follow-Up Studies | 18 | 2020 | 39050 | 0.140 |
Why?
|
| Galectin 3 | 1 | 2018 | 227 | 0.140 |
Why?
|
| Fatigue | 3 | 2019 | 1531 | 0.140 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 1 | 2018 | 245 | 0.140 |
Why?
|
| Infectious Disease Medicine | 1 | 2016 | 46 | 0.140 |
Why?
|
| Vision Disorders | 3 | 2018 | 1058 | 0.140 |
Why?
|
| C-Reactive Protein | 6 | 2020 | 3778 | 0.140 |
Why?
|
| Risk Factors | 17 | 2023 | 72290 | 0.140 |
Why?
|
| Reproducibility of Results | 7 | 2019 | 19905 | 0.140 |
Why?
|
| Doxycycline | 2 | 2010 | 326 | 0.140 |
Why?
|
| Observer Variation | 3 | 2016 | 2593 | 0.140 |
Why?
|
| Arthritis | 3 | 2013 | 659 | 0.140 |
Why?
|
| Injections, Subcutaneous | 1 | 2017 | 666 | 0.140 |
Why?
|
| Magnetic Resonance Imaging | 17 | 2021 | 35421 | 0.130 |
Why?
|
| Immunohistochemistry | 7 | 2015 | 11366 | 0.130 |
Why?
|
| Nose | 2 | 2013 | 509 | 0.130 |
Why?
|
| Acanthosis Nigricans | 1 | 1995 | 48 | 0.130 |
Why?
|
| Adolescent | 19 | 2022 | 85781 | 0.130 |
Why?
|
| Staining and Labeling | 1 | 2020 | 1100 | 0.130 |
Why?
|
| Urinalysis | 1 | 2018 | 369 | 0.130 |
Why?
|
| Fatal Outcome | 2 | 2018 | 1850 | 0.130 |
Why?
|
| Prosthesis Failure | 1 | 2021 | 1206 | 0.130 |
Why?
|
| Penis | 1 | 2016 | 216 | 0.130 |
Why?
|
| Lymphomatoid Granulomatosis | 1 | 2015 | 16 | 0.130 |
Why?
|
| Thromboangiitis Obliterans | 2 | 2007 | 10 | 0.130 |
Why?
|
| Lymphocytes | 2 | 2014 | 2617 | 0.130 |
Why?
|
| Pancreatitis, Chronic | 3 | 2013 | 285 | 0.130 |
Why?
|
| Clinical Trials as Topic | 4 | 2006 | 7913 | 0.130 |
Why?
|
| Heroin Dependence | 2 | 2013 | 175 | 0.130 |
Why?
|
| Immunoassay | 2 | 2020 | 752 | 0.130 |
Why?
|
| Matrix Metalloproteinase 3 | 2 | 2012 | 134 | 0.130 |
Why?
|
| Eyelids | 1 | 2017 | 265 | 0.130 |
Why?
|
| Hypertrophy | 2 | 2014 | 569 | 0.130 |
Why?
|
| Proteinuria | 1 | 2018 | 658 | 0.130 |
Why?
|
| Leukocyte Elastase | 1 | 2015 | 113 | 0.120 |
Why?
|
| Neurologic Examination | 1 | 2018 | 930 | 0.120 |
Why?
|
| Pulmonary Medicine | 1 | 2016 | 213 | 0.120 |
Why?
|
| Antibody-Producing Cells | 1 | 2014 | 143 | 0.120 |
Why?
|
| Granzymes | 3 | 2023 | 271 | 0.120 |
Why?
|
| Hypereosinophilic Syndrome | 1 | 2015 | 93 | 0.120 |
Why?
|
| Porphyria, Erythropoietic | 1 | 2013 | 9 | 0.120 |
Why?
|
| Epitope Mapping | 1 | 2015 | 311 | 0.120 |
Why?
|
| Arthralgia | 3 | 2020 | 456 | 0.120 |
Why?
|
| Time Factors | 10 | 2021 | 40075 | 0.120 |
Why?
|
| Immunoconjugates | 1 | 2001 | 901 | 0.120 |
Why?
|
| Apoptosis | 2 | 2020 | 9727 | 0.120 |
Why?
|
| Rehabilitation, Vocational | 1 | 2014 | 82 | 0.120 |
Why?
|
| Uveitis, Anterior | 1 | 2014 | 101 | 0.120 |
Why?
|
| Pituitary Gland | 1 | 2016 | 665 | 0.120 |
Why?
|
| Maxillary Diseases | 1 | 2013 | 51 | 0.120 |
Why?
|
| Bayes Theorem | 1 | 2021 | 2309 | 0.110 |
Why?
|
| Neck Injuries | 1 | 2015 | 152 | 0.110 |
Why?
|
| Diffusion of Innovation | 1 | 2018 | 725 | 0.110 |
Why?
|
| Withholding Treatment | 1 | 2018 | 599 | 0.110 |
Why?
|
| Granulocytes | 1 | 2015 | 548 | 0.110 |
Why?
|
| Pharyngeal Diseases | 1 | 2014 | 133 | 0.110 |
Why?
|
| Survival Rate | 5 | 2015 | 12788 | 0.110 |
Why?
|
| Antibodies, Blocking | 1 | 2014 | 253 | 0.110 |
Why?
|
| Communication | 1 | 2007 | 3749 | 0.110 |
Why?
|
| Calciphylaxis | 1 | 2015 | 124 | 0.110 |
Why?
|
| Spondylitis, Ankylosing | 1 | 2014 | 156 | 0.110 |
Why?
|
| Semaphorins | 1 | 2013 | 101 | 0.110 |
Why?
|
| Indicators and Reagents | 1 | 2014 | 462 | 0.110 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2017 | 1369 | 0.110 |
Why?
|
| Hypersensitivity | 1 | 2022 | 1102 | 0.110 |
Why?
|
| Administration, Oral | 4 | 2015 | 3913 | 0.110 |
Why?
|
| Aorta, Abdominal | 2 | 2013 | 646 | 0.110 |
Why?
|
| Age Factors | 4 | 2018 | 18370 | 0.110 |
Why?
|
| Cholesterol, HDL | 1 | 2019 | 1814 | 0.110 |
Why?
|
| Epistaxis | 1 | 2013 | 111 | 0.110 |
Why?
|
| Attitude to Computers | 2 | 2018 | 202 | 0.110 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2023 | 2916 | 0.110 |
Why?
|
| Acute Disease | 3 | 2013 | 7149 | 0.110 |
Why?
|
| Neutrophils | 4 | 2019 | 3719 | 0.110 |
Why?
|
| Nephrology | 1 | 2016 | 263 | 0.110 |
Why?
|
| Back Pain | 2 | 2014 | 545 | 0.110 |
Why?
|
| Peptide Fragments | 1 | 2005 | 5097 | 0.110 |
Why?
|
| Boston | 3 | 2021 | 9313 | 0.100 |
Why?
|
| Aneurysm, Infected | 1 | 2012 | 85 | 0.100 |
Why?
|
| Interferon-gamma | 2 | 2016 | 3206 | 0.100 |
Why?
|
| Multicenter Studies as Topic | 2 | 2021 | 1677 | 0.100 |
Why?
|
| Perception | 1 | 2018 | 1198 | 0.100 |
Why?
|
| Immunoglobulin M | 1 | 2017 | 1537 | 0.100 |
Why?
|
| Prevalence | 4 | 2023 | 15226 | 0.100 |
Why?
|
| Pulmonary Embolism | 2 | 2019 | 2376 | 0.100 |
Why?
|
| Arthrodesis | 1 | 2013 | 189 | 0.100 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2013 | 180 | 0.100 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2017 | 986 | 0.100 |
Why?
|
| Pemphigoid, Bullous | 1 | 2013 | 109 | 0.100 |
Why?
|
| United States | 17 | 2022 | 69872 | 0.100 |
Why?
|
| Self-Assessment | 1 | 2014 | 390 | 0.100 |
Why?
|
| Systemic Vasculitis | 1 | 2012 | 37 | 0.100 |
Why?
|
| Polyradiculopathy | 1 | 2011 | 23 | 0.100 |
Why?
|
| Paraneoplastic Syndromes, Nervous System | 1 | 2011 | 23 | 0.100 |
Why?
|
| Coronary Vessels | 1 | 2023 | 3107 | 0.100 |
Why?
|
| Antibodies, Neutralizing | 1 | 2021 | 1978 | 0.100 |
Why?
|
| Hashimoto Disease | 1 | 2012 | 97 | 0.100 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2016 | 2282 | 0.100 |
Why?
|
| Sweet Syndrome | 1 | 2011 | 47 | 0.100 |
Why?
|
| Alleles | 5 | 2018 | 6933 | 0.100 |
Why?
|
| Primary Ovarian Insufficiency | 1 | 2011 | 115 | 0.100 |
Why?
|
| Retreatment | 1 | 2013 | 610 | 0.100 |
Why?
|
| Proportional Hazards Models | 4 | 2020 | 12354 | 0.100 |
Why?
|
| Pneumonia | 2 | 2015 | 2133 | 0.100 |
Why?
|
| Angiopoietin-2 | 1 | 2012 | 173 | 0.100 |
Why?
|
| Acetylesterase | 1 | 2010 | 14 | 0.090 |
Why?
|
| Glucose | 1 | 2023 | 4397 | 0.090 |
Why?
|
| Genetic Predisposition to Disease | 7 | 2018 | 17446 | 0.090 |
Why?
|
| Mouth Mucosa | 1 | 2013 | 434 | 0.090 |
Why?
|
| Cholesterol | 1 | 2019 | 2917 | 0.090 |
Why?
|
| Europe | 5 | 2019 | 3339 | 0.090 |
Why?
|
| Submandibular Gland Diseases | 1 | 2010 | 21 | 0.090 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2015 | 793 | 0.090 |
Why?
|
| Carboxylic Ester Hydrolases | 1 | 2010 | 98 | 0.090 |
Why?
|
| Ischemia | 1 | 1999 | 1907 | 0.090 |
Why?
|
| Chin | 1 | 2010 | 38 | 0.090 |
Why?
|
| Osteoporosis | 2 | 2016 | 1580 | 0.090 |
Why?
|
| Ophthalmology | 1 | 2016 | 508 | 0.090 |
Why?
|
| Glaucoma | 2 | 2016 | 1159 | 0.090 |
Why?
|
| Parotid Diseases | 1 | 2010 | 46 | 0.090 |
Why?
|
| Papilledema | 1 | 2011 | 118 | 0.090 |
Why?
|
| Secondary Prevention | 2 | 2014 | 1530 | 0.090 |
Why?
|
| Erythrocytes | 1 | 2019 | 2455 | 0.090 |
Why?
|
| Sublingual Gland | 1 | 2009 | 10 | 0.090 |
Why?
|
| Cholesterol, LDL | 1 | 2019 | 2356 | 0.090 |
Why?
|
| Disease Susceptibility | 1 | 2017 | 1782 | 0.090 |
Why?
|
| N-Acetylneuraminic Acid | 1 | 2010 | 177 | 0.090 |
Why?
|
| Tongue Diseases | 1 | 2010 | 67 | 0.090 |
Why?
|
| Livedo Reticularis | 1 | 2009 | 5 | 0.090 |
Why?
|
| Mesenchymal Stem Cells | 1 | 2020 | 1632 | 0.090 |
Why?
|
| Cognition Disorders | 1 | 2004 | 4043 | 0.090 |
Why?
|
| Comorbidity | 4 | 2018 | 10388 | 0.090 |
Why?
|
| Hospitalization | 3 | 2021 | 10262 | 0.090 |
Why?
|
| E-Selectin | 1 | 2011 | 579 | 0.090 |
Why?
|
| Bone Density | 1 | 2022 | 3468 | 0.090 |
Why?
|
| Syndecan-1 | 1 | 2010 | 165 | 0.090 |
Why?
|
| Macrophages | 2 | 2021 | 5655 | 0.080 |
Why?
|
| Pyoderma Gangrenosum | 1 | 2010 | 76 | 0.080 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2023 | 1836 | 0.080 |
Why?
|
| Intention to Treat Analysis | 1 | 2010 | 426 | 0.080 |
Why?
|
| Cross-Sectional Studies | 7 | 2020 | 25043 | 0.080 |
Why?
|
| Brain Diseases | 1 | 1998 | 1563 | 0.080 |
Why?
|
| Nasal Cavity | 1 | 2011 | 313 | 0.080 |
Why?
|
| Aortic Rupture | 1 | 2012 | 310 | 0.080 |
Why?
|
| Ganglia, Spinal | 1 | 2011 | 519 | 0.080 |
Why?
|
| Veins | 1 | 2013 | 770 | 0.080 |
Why?
|
| Lipids | 1 | 2019 | 3305 | 0.080 |
Why?
|
| Universities | 1 | 2014 | 956 | 0.080 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2013 | 525 | 0.080 |
Why?
|
| Echocardiography | 1 | 2021 | 5102 | 0.080 |
Why?
|
| Vascular System Injuries | 1 | 2011 | 250 | 0.080 |
Why?
|
| Hand | 1 | 2013 | 884 | 0.080 |
Why?
|
| Mythology | 1 | 2007 | 15 | 0.080 |
Why?
|
| Complement System Proteins | 1 | 2011 | 795 | 0.080 |
Why?
|
| Activities of Daily Living | 3 | 2008 | 2418 | 0.080 |
Why?
|
| Venous Thromboembolism | 2 | 2019 | 1671 | 0.080 |
Why?
|
| Immunoglobulin A | 1 | 2011 | 992 | 0.080 |
Why?
|
| Antibodies, Anticardiolipin | 1 | 2007 | 62 | 0.080 |
Why?
|
| Polymorphism, Single Nucleotide | 6 | 2023 | 15519 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2016 | 6538 | 0.080 |
Why?
|
| Kidney Glomerulus | 2 | 2002 | 697 | 0.080 |
Why?
|
| Databases, Bibliographic | 1 | 2008 | 128 | 0.080 |
Why?
|
| Empirical Research | 1 | 2008 | 120 | 0.080 |
Why?
|
| Antibodies, Antinuclear | 3 | 2010 | 326 | 0.080 |
Why?
|
| Immunoglobulins, Intravenous | 2 | 2022 | 652 | 0.070 |
Why?
|
| Tinnitus | 1 | 2010 | 195 | 0.070 |
Why?
|
| Endothelial Cells | 1 | 2020 | 3479 | 0.070 |
Why?
|
| Myocardial Infarction | 2 | 2021 | 11727 | 0.070 |
Why?
|
| Forecasting | 1 | 2016 | 2951 | 0.070 |
Why?
|
| Cerebrovascular Disorders | 1 | 1994 | 1504 | 0.070 |
Why?
|
| Platelet Activation | 1 | 2011 | 673 | 0.070 |
Why?
|
| Ovary | 1 | 2011 | 981 | 0.070 |
Why?
|
| Promoter Regions, Genetic | 1 | 2018 | 5867 | 0.070 |
Why?
|
| Immunologic Memory | 1 | 2013 | 1348 | 0.070 |
Why?
|
| Perforin | 2 | 2018 | 168 | 0.070 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2011 | 841 | 0.070 |
Why?
|
| Interleukins | 2 | 2002 | 791 | 0.070 |
Why?
|
| Vocabulary, Controlled | 1 | 2008 | 170 | 0.070 |
Why?
|
| Respiratory Muscles | 1 | 2007 | 139 | 0.070 |
Why?
|
| Dura Mater | 1 | 2008 | 291 | 0.070 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2021 | 3143 | 0.070 |
Why?
|
| Vocal Cord Paralysis | 1 | 2010 | 267 | 0.070 |
Why?
|
| Boronic Acids | 1 | 2011 | 965 | 0.070 |
Why?
|
| Dermatology | 1 | 2016 | 872 | 0.070 |
Why?
|
| Muscular Diseases | 2 | 2008 | 556 | 0.070 |
Why?
|
| Abdominal Pain | 1 | 2012 | 1063 | 0.070 |
Why?
|
| Ischemic Attack, Transient | 1 | 2012 | 935 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 3 | 2004 | 6171 | 0.070 |
Why?
|
| Lymphocyte Activation | 4 | 2018 | 5524 | 0.070 |
Why?
|
| Urticaria | 2 | 2011 | 150 | 0.070 |
Why?
|
| Cause of Death | 3 | 2021 | 3584 | 0.070 |
Why?
|
| Positron-Emission Tomography | 2 | 2018 | 6234 | 0.060 |
Why?
|
| Neck | 1 | 2009 | 697 | 0.060 |
Why?
|
| Kidney Neoplasms | 1 | 2021 | 4262 | 0.060 |
Why?
|
| Liability, Legal | 1 | 2006 | 213 | 0.060 |
Why?
|
| Thrombophilia | 1 | 2007 | 305 | 0.060 |
Why?
|
| Animals | 7 | 2018 | 168757 | 0.060 |
Why?
|
| Pyrazines | 1 | 2011 | 1230 | 0.060 |
Why?
|
| Parvovirus B19, Human | 1 | 2004 | 38 | 0.060 |
Why?
|
| Crohn Disease | 2 | 2017 | 2303 | 0.060 |
Why?
|
| Carotid Stenosis | 1 | 2012 | 854 | 0.060 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2023 | 4479 | 0.060 |
Why?
|
| Pacemaker, Artificial | 1 | 2010 | 816 | 0.060 |
Why?
|
| Lymphatic Diseases | 1 | 2006 | 324 | 0.060 |
Why?
|
| Virus Diseases | 2 | 2011 | 711 | 0.060 |
Why?
|
| Herpesviridae | 1 | 2004 | 109 | 0.060 |
Why?
|
| Adrenal Cortex Hormones | 3 | 2016 | 1855 | 0.060 |
Why?
|
| Communication Aids for Disabled | 1 | 2004 | 56 | 0.060 |
Why?
|
| Psychiatry | 1 | 2016 | 1695 | 0.060 |
Why?
|
| Ear | 1 | 2004 | 173 | 0.060 |
Why?
|
| Narration | 1 | 2006 | 212 | 0.060 |
Why?
|
| Immunoglobulin D | 1 | 2023 | 56 | 0.060 |
Why?
|
| Delusions | 1 | 2006 | 300 | 0.060 |
Why?
|
| Gene Frequency | 3 | 2018 | 3588 | 0.060 |
Why?
|
| Polyuria | 2 | 2016 | 39 | 0.060 |
Why?
|
| Herpes Zoster | 1 | 2005 | 264 | 0.060 |
Why?
|
| Receptors, CXCR5 | 1 | 2023 | 92 | 0.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2021 | 11524 | 0.060 |
Why?
|
| Combined Modality Therapy | 2 | 2010 | 8642 | 0.060 |
Why?
|
| Amyloidosis | 1 | 2010 | 795 | 0.060 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2005 | 472 | 0.060 |
Why?
|
| Efficiency, Organizational | 1 | 2008 | 695 | 0.060 |
Why?
|
| Renal Dialysis | 4 | 2005 | 1786 | 0.060 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2016 | 2988 | 0.060 |
Why?
|
| Still's Disease, Adult-Onset | 1 | 2002 | 19 | 0.050 |
Why?
|
| Genetic Loci | 1 | 2012 | 2575 | 0.050 |
Why?
|
| Age of Onset | 2 | 2015 | 3271 | 0.050 |
Why?
|
| Antibodies | 3 | 2016 | 2460 | 0.050 |
Why?
|
| Salivary Glands, Minor | 1 | 2022 | 27 | 0.050 |
Why?
|
| Transportation of Patients | 1 | 2004 | 185 | 0.050 |
Why?
|
| Endothelium, Vascular | 2 | 2007 | 4456 | 0.050 |
Why?
|
| T-Lymphocytes | 2 | 2017 | 10180 | 0.050 |
Why?
|
| Genotype | 5 | 2018 | 12951 | 0.050 |
Why?
|
| Commerce | 1 | 2008 | 592 | 0.050 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2005 | 550 | 0.050 |
Why?
|
| Liver Diseases | 1 | 2011 | 1253 | 0.050 |
Why?
|
| Autoimmunity | 1 | 2010 | 1349 | 0.050 |
Why?
|
| Germ-Line Mutation | 1 | 2010 | 1788 | 0.050 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2008 | 2559 | 0.050 |
Why?
|
| Postoperative Complications | 3 | 2014 | 15295 | 0.050 |
Why?
|
| Splenic Artery | 1 | 2002 | 54 | 0.050 |
Why?
|
| Indomethacin | 1 | 2002 | 332 | 0.050 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2005 | 638 | 0.050 |
Why?
|
| Disease Models, Animal | 2 | 2018 | 18029 | 0.050 |
Why?
|
| Databases, Factual | 1 | 2017 | 7729 | 0.050 |
Why?
|
| Polymorphism, Genetic | 1 | 2012 | 4328 | 0.050 |
Why?
|
| Monocytes | 2 | 2017 | 2596 | 0.050 |
Why?
|
| Logistic Models | 2 | 2020 | 13408 | 0.050 |
Why?
|
| Child | 5 | 2022 | 77709 | 0.050 |
Why?
|
| Genetic Variation | 2 | 2019 | 6544 | 0.050 |
Why?
|
| Vasculitis, Central Nervous System | 1 | 2001 | 42 | 0.050 |
Why?
|
| Diabetes Mellitus | 2 | 2016 | 5751 | 0.050 |
Why?
|
| Neovascularization, Pathologic | 1 | 2011 | 2635 | 0.050 |
Why?
|
| Pediatrics | 1 | 2016 | 3475 | 0.050 |
Why?
|
| Colitis, Ulcerative | 1 | 2013 | 1912 | 0.050 |
Why?
|
| Salivary Glands | 1 | 2022 | 229 | 0.050 |
Why?
|
| Erythema | 2 | 2001 | 257 | 0.050 |
Why?
|
| RNA, Messenger | 1 | 2016 | 13033 | 0.050 |
Why?
|
| Skin Pigmentation | 1 | 2023 | 282 | 0.050 |
Why?
|
| Bacteroidetes | 1 | 2021 | 83 | 0.050 |
Why?
|
| Cysts | 1 | 2006 | 678 | 0.050 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2007 | 1205 | 0.050 |
Why?
|
| Cardiovascular Diseases | 4 | 2020 | 15165 | 0.050 |
Why?
|
| Peripheral Nerves | 1 | 2004 | 466 | 0.050 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2023 | 548 | 0.050 |
Why?
|
| Informatics | 1 | 2021 | 72 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 2 | 2012 | 7279 | 0.050 |
Why?
|
| Gelatinases | 1 | 2020 | 94 | 0.050 |
Why?
|
| Curriculum | 1 | 2014 | 3605 | 0.050 |
Why?
|
| Patients | 1 | 2007 | 900 | 0.050 |
Why?
|
| Medical Futility | 1 | 2021 | 127 | 0.050 |
Why?
|
| Models, Organizational | 1 | 2004 | 574 | 0.050 |
Why?
|
| Chronic Disease | 3 | 2010 | 9146 | 0.050 |
Why?
|
| Eye | 1 | 2004 | 729 | 0.040 |
Why?
|
| Interleukin-13 | 1 | 2022 | 389 | 0.040 |
Why?
|
| History, 19th Century | 1 | 2002 | 720 | 0.040 |
Why?
|
| Research Design | 2 | 2011 | 5987 | 0.040 |
Why?
|
| Immunophenotyping | 2 | 2015 | 1880 | 0.040 |
Why?
|
| Serine Endopeptidases | 2 | 2020 | 1072 | 0.040 |
Why?
|
| Medical History Taking | 1 | 2003 | 783 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 2 | 2010 | 7181 | 0.040 |
Why?
|
| Phthalazines | 1 | 2021 | 363 | 0.040 |
Why?
|
| Physicians | 3 | 2014 | 4567 | 0.040 |
Why?
|
| Americas | 1 | 2019 | 111 | 0.040 |
Why?
|
| Risk Assessment | 5 | 2021 | 23338 | 0.040 |
Why?
|
| Aortic Diseases | 1 | 2005 | 742 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2021 | 629 | 0.040 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2007 | 808 | 0.040 |
Why?
|
| Molecular Biology | 1 | 2003 | 596 | 0.040 |
Why?
|
| Phenotype | 4 | 2019 | 16365 | 0.040 |
Why?
|
| Haplotypes | 2 | 2017 | 2779 | 0.040 |
Why?
|
| Mental Health | 2 | 2022 | 3019 | 0.040 |
Why?
|
| Histoplasma | 1 | 1998 | 41 | 0.040 |
Why?
|
| Graft Survival | 2 | 1999 | 3737 | 0.040 |
Why?
|
| Immunosorbent Techniques | 1 | 2018 | 184 | 0.040 |
Why?
|
| Rhinitis | 1 | 2006 | 691 | 0.040 |
Why?
|
| HLA-DR Antigens | 1 | 2020 | 645 | 0.040 |
Why?
|
| Guidelines as Topic | 1 | 2005 | 1405 | 0.040 |
Why?
|
| Glomerular Mesangium | 1 | 1998 | 108 | 0.040 |
Why?
|
| False Positive Reactions | 1 | 2000 | 981 | 0.040 |
Why?
|
| Antigens, Differentiation | 1 | 2001 | 927 | 0.040 |
Why?
|
| Reagent Strips | 1 | 2018 | 39 | 0.040 |
Why?
|
| Capillary Permeability | 1 | 2021 | 798 | 0.040 |
Why?
|
| Connective Tissue Diseases | 1 | 2001 | 264 | 0.040 |
Why?
|
| Pulmonary Veins | 1 | 2004 | 761 | 0.040 |
Why?
|
| Weight Gain | 1 | 2008 | 2292 | 0.040 |
Why?
|
| DNA, Viral | 1 | 2004 | 2225 | 0.040 |
Why?
|
| HLA-DP Antigens | 1 | 2017 | 28 | 0.040 |
Why?
|
| Signal Transduction | 2 | 2021 | 23403 | 0.040 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2018 | 294 | 0.040 |
Why?
|
| Likelihood Functions | 1 | 2000 | 1005 | 0.040 |
Why?
|
| Immunomodulation | 1 | 2021 | 541 | 0.040 |
Why?
|
| Proteins | 1 | 2012 | 6103 | 0.040 |
Why?
|
| Asia | 1 | 2019 | 610 | 0.040 |
Why?
|
| Glomerular Filtration Rate | 2 | 2017 | 2170 | 0.040 |
Why?
|
| Giant Cells | 1 | 1997 | 187 | 0.040 |
Why?
|
| DNA, Bacterial | 1 | 2002 | 1465 | 0.040 |
Why?
|
| Uncertainty | 1 | 2022 | 734 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 2000 | 1590 | 0.040 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily B | 1 | 2016 | 82 | 0.040 |
Why?
|
| Cerebral Angiography | 2 | 2001 | 1285 | 0.040 |
Why?
|
| Receptors, CCR4 | 1 | 2016 | 81 | 0.040 |
Why?
|
| Endopeptidases | 1 | 2020 | 772 | 0.040 |
Why?
|
| Chemokine CCL4 | 1 | 2016 | 128 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2012 | 4599 | 0.040 |
Why?
|
| Interleukin-10 | 1 | 2022 | 1200 | 0.040 |
Why?
|
| Species Specificity | 1 | 2021 | 2478 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2005 | 3772 | 0.040 |
Why?
|
| Sweating | 1 | 2017 | 123 | 0.040 |
Why?
|
| Cell Proliferation | 3 | 2018 | 10481 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2002 | 1534 | 0.030 |
Why?
|
| Epitopes | 1 | 2023 | 2571 | 0.030 |
Why?
|
| Microsatellite Repeats | 1 | 2018 | 802 | 0.030 |
Why?
|
| Histocompatibility Testing | 1 | 1998 | 741 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 1998 | 1420 | 0.030 |
Why?
|
| Cell Size | 1 | 1998 | 643 | 0.030 |
Why?
|
| Diabetes Insipidus | 1 | 2016 | 151 | 0.030 |
Why?
|
| Pulse Therapy, Drug | 1 | 2015 | 35 | 0.030 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 1038 | 0.030 |
Why?
|
| Immunologic Tests | 1 | 2016 | 103 | 0.030 |
Why?
|
| Transforming Growth Factor beta | 1 | 2023 | 2007 | 0.030 |
Why?
|
| Chemokine CCL5 | 1 | 2016 | 209 | 0.030 |
Why?
|
| Nephrectomy | 1 | 2021 | 1050 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2021 | 1915 | 0.030 |
Why?
|
| Antiviral Agents | 2 | 2021 | 2987 | 0.030 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2016 | 310 | 0.030 |
Why?
|
| Limit of Detection | 1 | 2016 | 265 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2019 | 1341 | 0.030 |
Why?
|
| Chi-Square Distribution | 2 | 2013 | 3508 | 0.030 |
Why?
|
| Mice | 3 | 2018 | 81183 | 0.030 |
Why?
|
| Pancreatic Neoplasms | 1 | 2013 | 5256 | 0.030 |
Why?
|
| Quinolines | 1 | 2020 | 732 | 0.030 |
Why?
|
| Urethra | 1 | 1997 | 408 | 0.030 |
Why?
|
| Immunoglobulin Class Switching | 1 | 2017 | 291 | 0.030 |
Why?
|
| Pulmonary Artery | 1 | 2004 | 1912 | 0.030 |
Why?
|
| Quinazolines | 1 | 2021 | 1356 | 0.030 |
Why?
|
| Graft Rejection | 2 | 1998 | 4397 | 0.030 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2016 | 276 | 0.030 |
Why?
|
| Necrosis | 1 | 1999 | 1643 | 0.030 |
Why?
|
| Morbidity | 1 | 2020 | 1769 | 0.030 |
Why?
|
| Nasal Septum | 1 | 2016 | 127 | 0.030 |
Why?
|
| HLA-B27 Antigen | 1 | 2014 | 76 | 0.030 |
Why?
|
| Binding Sites, Antibody | 1 | 2015 | 349 | 0.030 |
Why?
|
| Immunoglobulins | 1 | 2018 | 881 | 0.030 |
Why?
|
| Fibromuscular Dysplasia | 1 | 2015 | 58 | 0.030 |
Why?
|
| Gene Expression | 2 | 2018 | 7799 | 0.030 |
Why?
|
| Tacrolimus | 1 | 1998 | 743 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2023 | 2540 | 0.030 |
Why?
|
| History, 20th Century | 1 | 2002 | 2740 | 0.030 |
Why?
|
| Antibody Diversity | 1 | 2014 | 74 | 0.030 |
Why?
|
| Acromegaly | 1 | 1997 | 346 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2018 | 805 | 0.030 |
Why?
|
| Weight Loss | 2 | 2017 | 2622 | 0.030 |
Why?
|
| Stomach Ulcer | 1 | 2014 | 125 | 0.030 |
Why?
|
| Social Support | 1 | 2004 | 2118 | 0.030 |
Why?
|
| Somatic Hypermutation, Immunoglobulin | 1 | 2014 | 97 | 0.030 |
Why?
|
| Cadaver | 1 | 1998 | 1337 | 0.030 |
Why?
|
| Waiting Lists | 1 | 2018 | 692 | 0.030 |
Why?
|
| Radiography, Thoracic | 1 | 2000 | 1265 | 0.030 |
Why?
|
| Brain Edema | 1 | 1998 | 617 | 0.030 |
Why?
|
| T-Box Domain Proteins | 1 | 2016 | 471 | 0.030 |
Why?
|
| Allosteric Regulation | 1 | 2015 | 408 | 0.030 |
Why?
|
| Software | 1 | 2008 | 4443 | 0.030 |
Why?
|
| Cervix Uteri | 1 | 1997 | 590 | 0.030 |
Why?
|
| Esophageal Diseases | 1 | 2014 | 166 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2007 | 3843 | 0.030 |
Why?
|
| Extracellular Matrix | 1 | 2021 | 1741 | 0.030 |
Why?
|
| Knee | 1 | 2014 | 274 | 0.030 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2015 | 659 | 0.030 |
Why?
|
| Heart Block | 1 | 2014 | 410 | 0.030 |
Why?
|
| Family | 1 | 2004 | 3147 | 0.030 |
Why?
|
| Probability | 1 | 1998 | 2505 | 0.030 |
Why?
|
| Chemokine CXCL13 | 1 | 2012 | 54 | 0.030 |
Why?
|
| Kidney Function Tests | 1 | 2014 | 684 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2016 | 1572 | 0.030 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2016 | 644 | 0.030 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2012 | 149 | 0.030 |
Why?
|
| Stroke | 1 | 2015 | 9981 | 0.030 |
Why?
|
| Follicle Stimulating Hormone, Human | 1 | 2011 | 25 | 0.030 |
Why?
|
| Prostate | 1 | 2020 | 1774 | 0.030 |
Why?
|
| Lymph Nodes | 2 | 2016 | 3474 | 0.030 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2014 | 482 | 0.030 |
Why?
|
| User-Computer Interface | 1 | 2018 | 1431 | 0.030 |
Why?
|
| Multivariate Analysis | 2 | 2012 | 12245 | 0.030 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2020 | 2016 | 0.020 |
Why?
|
| Thyroid Function Tests | 1 | 2012 | 286 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2020 | 2250 | 0.020 |
Why?
|
| Isoxazoles | 1 | 2013 | 216 | 0.020 |
Why?
|
| Odds Ratio | 2 | 2017 | 9849 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2016 | 2297 | 0.020 |
Why?
|
| Meningitis, Aseptic | 1 | 2011 | 58 | 0.020 |
Why?
|
| Muscle Weakness | 1 | 2014 | 413 | 0.020 |
Why?
|
| Pulmonary Atelectasis | 2 | 2004 | 145 | 0.020 |
Why?
|
| Piperazines | 1 | 2021 | 2488 | 0.020 |
Why?
|
| Transplantation Conditioning | 1 | 1998 | 1598 | 0.020 |
Why?
|
| Central Nervous System | 1 | 1998 | 1357 | 0.020 |
Why?
|
| Heart | 1 | 2004 | 4467 | 0.020 |
Why?
|
| Collagen | 1 | 2019 | 2689 | 0.020 |
Why?
|
| Interleukin-17 | 1 | 2016 | 899 | 0.020 |
Why?
|
| Clone Cells | 1 | 2014 | 1692 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2001 | 2684 | 0.020 |
Why?
|
| Electrodiagnosis | 1 | 2011 | 151 | 0.020 |
Why?
|
| Major Histocompatibility Complex | 1 | 2013 | 936 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2020 | 2645 | 0.020 |
Why?
|
| Respiration, Artificial | 1 | 2021 | 2569 | 0.020 |
Why?
|
| Gene Rearrangement | 1 | 2015 | 1179 | 0.020 |
Why?
|
| Sensation Disorders | 1 | 2011 | 155 | 0.020 |
Why?
|
| Paresthesia | 1 | 2011 | 161 | 0.020 |
Why?
|
| Membrane Glycoproteins | 1 | 2001 | 3768 | 0.020 |
Why?
|
| Peripheral Nervous System | 1 | 2011 | 150 | 0.020 |
Why?
|
| Leukocytosis | 1 | 2011 | 247 | 0.020 |
Why?
|
| Telemedicine | 1 | 2007 | 2872 | 0.020 |
Why?
|
| Thoracic Vertebrae | 1 | 2014 | 608 | 0.020 |
Why?
|
| Biocatalysis | 1 | 2010 | 167 | 0.020 |
Why?
|
| Longitudinal Studies | 2 | 2019 | 13989 | 0.020 |
Why?
|
| Phenytoin | 1 | 1970 | 197 | 0.020 |
Why?
|
| Cell Communication | 1 | 2017 | 1621 | 0.020 |
Why?
|
| Anti-Mullerian Hormone | 1 | 2011 | 402 | 0.020 |
Why?
|
| Gastritis | 1 | 2011 | 196 | 0.020 |
Why?
|
| Forkhead Transcription Factors | 1 | 2016 | 1613 | 0.020 |
Why?
|
| CD40 Ligand | 1 | 2011 | 526 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 1998 | 6365 | 0.020 |
Why?
|
| Bone Marrow Transplantation | 1 | 1997 | 2765 | 0.020 |
Why?
|
| Antigen-Antibody Reactions | 1 | 2009 | 363 | 0.020 |
Why?
|
| Laryngoscopy | 1 | 2014 | 711 | 0.020 |
Why?
|
| Massachusetts | 1 | 2021 | 8663 | 0.020 |
Why?
|
| Angiography | 1 | 1994 | 1639 | 0.020 |
Why?
|
| Cells, Cultured | 2 | 2019 | 19229 | 0.020 |
Why?
|
| P-Selectin | 1 | 2011 | 600 | 0.020 |
Why?
|
| Patient Selection | 1 | 2000 | 4215 | 0.020 |
Why?
|
| Aspirin | 2 | 2012 | 3282 | 0.020 |
Why?
|
| Chemokine CCL2 | 1 | 2011 | 617 | 0.020 |
Why?
|
| Models, Biological | 1 | 2005 | 9583 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2018 | 6622 | 0.020 |
Why?
|
| Membrane Proteins | 2 | 2020 | 7880 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2010 | 553 | 0.020 |
Why?
|
| Chemokines | 1 | 2012 | 970 | 0.020 |
Why?
|
| Creatinine | 2 | 2005 | 1919 | 0.020 |
Why?
|
| Aortic Valve Stenosis | 1 | 2020 | 1965 | 0.020 |
Why?
|
| Interleukin-8 | 1 | 2011 | 690 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2013 | 2029 | 0.020 |
Why?
|
| Intestine, Small | 1 | 2014 | 1241 | 0.020 |
Why?
|
| Cathepsin G | 1 | 2007 | 32 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2019 | 3743 | 0.020 |
Why?
|
| Cell Line, Transformed | 1 | 2009 | 898 | 0.020 |
Why?
|
| Acetylation | 1 | 2010 | 1085 | 0.020 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2020 | 3327 | 0.020 |
Why?
|
| Drug Eruptions | 1 | 1970 | 297 | 0.020 |
Why?
|
| Spondylarthritis | 1 | 2008 | 62 | 0.020 |
Why?
|
| Sample Size | 1 | 2010 | 845 | 0.020 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2007 | 428 | 0.020 |
Why?
|
| Cocaine-Related Disorders | 1 | 2010 | 460 | 0.020 |
Why?
|
| Umbilical Veins | 1 | 2007 | 433 | 0.020 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2011 | 388 | 0.020 |
Why?
|
| Neck Pain | 1 | 2008 | 180 | 0.020 |
Why?
|
| Cathepsins | 1 | 2007 | 241 | 0.020 |
Why?
|
| Multiple Sclerosis | 1 | 2021 | 3079 | 0.020 |
Why?
|
| Genome-Wide Association Study | 2 | 2017 | 12261 | 0.020 |
Why?
|
| SEER Program | 1 | 2011 | 1508 | 0.020 |
Why?
|
| Mental Disorders | 1 | 2006 | 6600 | 0.020 |
Why?
|
| Vasa Vasorum | 1 | 2005 | 26 | 0.020 |
Why?
|
| Glycosylation | 1 | 2009 | 1126 | 0.020 |
Why?
|
| Graft vs Host Disease | 1 | 1998 | 2957 | 0.020 |
Why?
|
| Elastic Tissue | 1 | 2005 | 65 | 0.020 |
Why?
|
| Survival Analysis | 1 | 1998 | 10252 | 0.020 |
Why?
|
| Lumbar Vertebrae | 1 | 2014 | 1848 | 0.020 |
Why?
|
| Tryptophan Oxygenase | 1 | 2004 | 19 | 0.020 |
Why?
|
| Hydroxychloroquine | 1 | 2009 | 412 | 0.020 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2007 | 362 | 0.020 |
Why?
|
| Parvoviridae Infections | 1 | 2004 | 35 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2018 | 7785 | 0.020 |
Why?
|
| ROC Curve | 1 | 2012 | 3527 | 0.020 |
Why?
|
| Heparin | 1 | 2012 | 1637 | 0.020 |
Why?
|
| Fractures, Bone | 1 | 2016 | 1947 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 2015 | 2585 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2011 | 2699 | 0.020 |
Why?
|
| Risk | 1 | 2016 | 9687 | 0.020 |
Why?
|
| Exons | 1 | 2010 | 2437 | 0.010 |
Why?
|
| Dry Eye Syndromes | 1 | 2009 | 386 | 0.010 |
Why?
|
| Plasma Exchange | 1 | 2005 | 152 | 0.010 |
Why?
|
| Genetic Association Studies | 1 | 2013 | 2703 | 0.010 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2004 | 109 | 0.010 |
Why?
|
| Random Allocation | 1 | 2008 | 2429 | 0.010 |
Why?
|
| Globins | 1 | 2004 | 415 | 0.010 |
Why?
|
| Medicare | 1 | 2021 | 6566 | 0.010 |
Why?
|
| Warfarin | 1 | 2012 | 1496 | 0.010 |
Why?
|
| Herpesviridae Infections | 1 | 2004 | 277 | 0.010 |
Why?
|
| Spinal Cord | 1 | 2011 | 1809 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2013 | 2948 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2015 | 5391 | 0.010 |
Why?
|
| Depression | 1 | 2022 | 7766 | 0.010 |
Why?
|
| Hyperplasia | 1 | 2005 | 1185 | 0.010 |
Why?
|
| Gadolinium DTPA | 1 | 2005 | 836 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2011 | 3494 | 0.010 |
Why?
|
| Liver Cirrhosis | 1 | 2011 | 1863 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2011 | 6459 | 0.010 |
Why?
|
| Heart Failure | 1 | 2004 | 10900 | 0.010 |
Why?
|
| International Cooperation | 1 | 2007 | 1420 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2018 | 21827 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2016 | 9438 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2011 | 3508 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2016 | 12720 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2010 | 4803 | 0.010 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2005 | 1504 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2012 | 5985 | 0.010 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2013 | 2425 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2021 | 41006 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 1998 | 25625 | 0.010 |
Why?
|
| Linear Models | 1 | 2008 | 5952 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2015 | 12072 | 0.010 |
Why?
|
| Pregnancy | 1 | 1998 | 29144 | 0.010 |
Why?
|
| Brain | 3 | 2011 | 26385 | 0.010 |
Why?
|
| Cell Line | 1 | 2010 | 15997 | 0.010 |
Why?
|
| Genomics | 1 | 2011 | 5720 | 0.010 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2008 | 1813 | 0.010 |
Why?
|
| Algorithms | 1 | 2016 | 13881 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2010 | 3336 | 0.010 |
Why?
|
| Neoplasm Proteins | 1 | 2007 | 3703 | 0.010 |
Why?
|
| Atrial Fibrillation | 1 | 2011 | 5034 | 0.010 |
Why?
|
| Contrast Media | 1 | 2005 | 5300 | 0.010 |
Why?
|
| Serum Globulins | 1 | 1970 | 24 | 0.010 |
Why?
|
| Blood Urea Nitrogen | 1 | 1970 | 191 | 0.010 |
Why?
|
| Health Surveys | 1 | 1999 | 4037 | 0.010 |
Why?
|
| Transaminases | 1 | 1970 | 199 | 0.010 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 1970 | 424 | 0.010 |
Why?
|
| Blood Chemical Analysis | 1 | 1970 | 440 | 0.000 |
Why?
|
| Alkaline Phosphatase | 1 | 1970 | 865 | 0.000 |
Why?
|
| Lung Neoplasms | 1 | 2011 | 13102 | 0.000 |
Why?
|
| Clinical Competence | 1 | 1981 | 4687 | 0.000 |
Why?
|
| Mutation | 1 | 2007 | 29786 | 0.000 |
Why?
|